P001: Advanced Immuno-Oncology Therapy

P001 is a cutting-edge biosimilar developed to target key immune pathways in the treatment of various cancers. Designed for patients with advanced-stage malignancies, P001 leverages the body's immune system to combat tumor cells effectively. With demonstrated safety and efficacy comparable to its reference product, P001 offers a cost-efficient solution while maintaining the highest standards of care.

Omexa Biologics is committed to expanding access to life-saving immunotherapies, with P001 leading our oncology biosimilar portfolio. Regulatory approval for P001 is anticipated in Q1 2027, with global expansion planned shortly thereafter.